Compositions and methods related to anti-EGFR antibody drug conjugates
US10118965B2 · kind B2 · utility
12Cited by
6References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 26, 2016 |
| Grant date | Nov 6, 2018 |
| Priority date | — |
| Expiry date | Sep 26, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/6889
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-epidermal growth factor receptor (“EGFR”) antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the drug; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.